HALO — Halozyme Therapeutics

Halozyme licenses the only commercially validated technology that converts intravenous biologics into subcutaneous injections — a business with a 64.75% EBITDA margin, royalties growing at 52% annually, and ten commercial products on the market with fifty more in partner pipelines — and the stock trades at 8.5 times forward earnings because the market categorizes it as a biotechnology company rather than the royalty infrastructure business it actually is. Three acquisitions in 2025 extended the intellectual property runway into the mid-2040s and expanded the platform from one delivery technology to three. Compelling at the current price.

---

The pharmaceutical industry is in the middle of a structural shift in how drugs are delivered, and most investors are watching it through the lens of individual products rather than through the infrastructure that makes the shift possible. When Janssen converts DARZALEX from a multi-hour intravenous infusion requiring a clinical setting to a five-minute subcutaneous injection a patient can receive at home, the commercial impact is decisive — DARZALEX SC has achieved 97% U.S. market share in the multiple myeloma franchise. When Roche converts its flagship MS therapy Ocrevus to subcutaneous administration, the Ocrevus franchise total sales target rises to CHF 9 billion. When argenx converts VYVGART to VYVGART Hytrulo, royalty revenue to Halozyme grows 444% year-over-year. In each case, the drug company's revenue expands significantly, the patient's treatment experience improves dramatically, and somewhere in San Diego, Halozyme collects a royalty on every unit sold.

The biologics market is the fastest-growing category in pharmaceuticals, projected to reach $500 billion annually by 2030. Biologics — protein-based therapies for cancer, autoimmune disease, and rare conditions — require precise delivery that has historically made intravenous administration the standard approach. An IV infusion for a cancer or immunology drug requires a trained nurse, a clinical infusion center, a multi-hour chair appointment, and repeat visits every two to four weeks for the life of the treatment. The cost and inconvenience of this delivery model are substantial and, for most patients, the dominant burden of managing a chronic condition. A drug that can be administered subcutaneously — under the skin, in thirty seconds to five minutes, at home — is not merely more convenient. It is a fundamentally different patient experience, with meaningfully better adherence, reduced clinical costs, and in many geographies, expanded access to patients who cannot easily reach infusion centers. When a biologic achieves subcutaneous conversion, market share doesn't just hold; it accelerates.

The mechanism that enables subcutaneous delivery of large-volume biologics — which cannot diffuse through subcutaneous tissue in their native form — is the temporary disruption of the hyaluronan matrix under the skin using a proprietary enzyme called recombinant human hyaluronidase (rHuPH20). This enzyme, developed and patented by Halozyme, is the ENHANZE technology. It works precisely once in the tissue, disperses, and leaves no lasting trace. It has been used in over one million patient administrations across ten commercial products in more than 100 countries, generating tens of billions of dollars in partner drug sales. The regulatory track record across FDA, EMA, and dozens of other health authorities is the product of fifteen years of accumulated clinical evidence. No competing technology has replicated this commercial track record. None has achieved a single commercial launch.

Halozyme does not make drugs. It does not run clinical trials. It does not employ a sales force or manage manufacturing. It licenses ENHANZE to pharmaceutical companies — currently twenty-plus active partnerships with Roche, Janssen, Pfizer, AbbVie, Takeda, argenx, Eli Lilly, Bristol-Myers Squibb, ViiV Healthcare, Merus, and others — collects upfront licensing fees and development milestone payments while the partner's SC version moves through clinical development, and then earns a royalty on every unit sold commercially, in perpetuity, until the relevant patents expire. The P&L looks pharmaceutical because the accounting standards don't have a "royalty infrastructure" category. The economics are something closer to a toll bridge: the structure was built once, the toll is collected on every vehicle that crosses, and the cost of maintaining the structure is modest relative to the volume of traffic it carries.

The moat in this business has three layers, each reinforcing the others. The first is scientific and regulatory validation: ENHANZE is the only hyaluronidase-based delivery technology with a decade of commercial approvals across multiple therapeutic categories and multiple regulatory agencies. A pharmaceutical company evaluating subcutaneous conversion for a $2 billion drug does not experiment with an unproven alternative — the clinical and regulatory risk of a failed or delayed SC conversion is measured in years and hundreds of millions of dollars. It uses ENHANZE because ENHANZE has worked, repeatedly, across drugs that don't share mechanisms, dosing volumes, or therapeutic indications. The second layer is formulation lock-in: once a pharmaceutical company commits to developing a subcutaneous version using ENHANZE, the formulation chemistry, the clinical trial design, the regulatory package, and the manufacturing process are all built around ENHANZE's enzyme. Switching platforms mid-development would require restarting from the formulation stage — a two-to-three year setback on a program where the drug itself may already have seven years left on patent. No company switches. The third layer is network compounding: every successful commercial launch adds to the safety database, the regulatory precedent, and the published clinical literature supporting ENHANZE use. Each new drug that converts and succeeds strengthens the argument for the next pharmaceutical company considering conversion.

The intelligence of the bear case is not to dispute these three moat layers but to question their duration. ENHANZE core patents in Europe were set to expire in 2025; Halozyme secured an extension to 2029. A similar extension application is pending in the United States. The patents that govern specific collaborations — the formulation patents filed jointly with each pharmaceutical partner for each drug — have longer durations and are drug-specific, meaning the royalty stream on DARZALEX SC continues for as long as DARZALEX SC has exclusivity, independent of the core ENHANZE patent. Merck's development of subcutaneous Keytruda using hyaluronidase technology without a Halozyme license prompted Halozyme to file patent infringement litigation in 2025 — a lawsuit that, if successful, converts Merck from a potential competitor into a new royalty partner. A company willing to sue a $200 billion pharmaceutical giant over its IP position is not one that doubts the strength of its patents.

The more substantial threat is that a competing subcutaneous delivery technology achieves commercial validation and begins displacing ENHANZE for future programs. This has not happened: Portal Instruments (needle-free jet injection), Enable Injections (on-body devices), and other approaches target different delivery challenges and have not produced a commercially approved biologic-conversion platform comparable to ENHANZE's scale. Halozyme's response to the underlying technology risk has been structural: in 2025, the company acquired Elektrofi's Hypercon technology (protein hyperconcentration, enabling even higher dose SC delivery) and Surf Bio (a novel hyperconcentration and dispersibility platform). Both technologies carry intellectual property extending into the mid-2040s. Halozyme entered 2026 with three royalty-bearing subcutaneous delivery technologies rather than one — a portfolio that addresses different delivery challenges and collectively covers a larger proportion of the biologics market than ENHANZE alone. The patent cliff concern that was legitimate in 2023 has been substantially mitigated by the mid-2040s IP horizon of the new acquisitions.

Full-year 2025 revenue was a record $1.397 billion, up 38% from $1.015 billion in 2024. Royalty revenue — the economic core of the business — grew 52% to $867.8 million, from $571.0 million in 2024. GAAP net income was $316.9 million, down from $444 million in 2024; the decline reflects acquisition-related costs and amortization from Elektrofi and Surf Bio, not operational deterioration. The more representative profitability figure is adjusted EBITDA, which the company has guided to $1.125 to $1.205 billion for 2026 — an EBITDA margin approaching 67% on $1.71 to $1.81 billion in 2026 total revenue guidance. Non-GAAP diluted EPS guidance for 2026 is $7.75 to $8.25. Return on equity is 124%, a figure that reflects a capital-light royalty model where incremental royalty revenue drops to the bottom line with minimal additional investment. The debt-to-equity ratio is elevated at 3.05x, a consequence of share repurchases and acquisitions funded with debt — a structure that warrants monitoring but is manageable given the free cash flow profile.

Free cash flow margin is 46.2% on a trailing basis. The capital requirements of a royalty business are minimal: Halozyme does not build manufacturing facilities, fund Phase 3 trials for partner drugs, or run a commercial sales organization. The primary capital use is R&D for its own technology platforms — specifically the enhancement and expansion of ENHANZE's capabilities and the development of the Hypercon and Surf Bio platforms. The remaining cash generation goes to debt repayment, share repurchases, and the acquisition of technology extensions. This is the capital allocation structure that will be familiar to investors in royalty models across industries: harvest the existing royalty stream, return surplus capital to shareholders, and invest selectively in extending the runway.

Helen Torley has served as CEO since 2014, presiding over the company's transformation from an experimental delivery technology business into a royalty-generating commercial platform. The capital allocation track record is shareholder-friendly: Halozyme completed the second tranche of its $750 million share repurchase program in mid-2025 and initiated the third $250 million tranche in June 2025, with share count declining approximately 3.3% year-over-year. The repurchases have been executed at prices well below what a royalty company with this growth profile should be worth — a judgment that has been consistently validated by the growing royalty trajectory. One near-term concern: CFO Nicole LaBrosse's planned departure effective March 2026, with an interim CFO appointed March 23, 2026, introduces brief financial leadership uncertainty. The underlying business economics are unaffected by CFO transitions; the concern is real but does not change the analytical conclusion.

The royalty revenue trajectory is the essential table for understanding this business. Each row represents the accumulated commercial output of a growing portfolio of approved drugs, each of which took three to five years to develop with ENHANZE before appearing in the royalty line:

Year	Total Revenue ($M)	Royalty Revenue ($M)	Royalty Growth	Commercial Products	GAAP Net Income ($M)
2020	$172	$36	—	~4	$6
2021	$210	$65	+80%	~6	$82
2022	$481	$196	+200%	~8	$162
2023	$718	$382	+95%	~10	$304
2024	$1,015	$571	+49%	~12	$444
2025	$1,397	$868	+52%	~15	$317
2026E	$1,710–1,810	$1,130–1,170	+30–35%	~15+	—

Royalty revenue grew from $36 million in 2020 to $868 million in 2025 — a 24-fold increase in five years, and the trajectory continues. This growth is not primarily a function of new partnerships signed during that period; it reflects the existing commercial partnerships ramping through physician and patient adoption as subcutaneous versions replaced IV administration at the point of prescription. DARZALEX SC royalty revenue reached $483 million in 2025, growing 29%, with the subcutaneous formulation at 97% U.S. market share in the multiple myeloma franchise and projected DARZALEX sales of $18 billion by 2028. VYVGART Hytrulo royalties reached $157.2 million, up 444% year-over-year, as argenx's rapid expansion across CIDP, gMG, and IgAN indications drove adoption globally. Phesgo royalties reached $105.6 million, up 51%, with global conversion from IV Perjeta reaching 54% in Q4 2025.

The three established blockbusters are all still growing and collectively represent the majority of current royalties. More important for the future is the second wave: Ocrevus Zunovo (subcutaneous MS therapy from Roche) reported 17,500 patients on therapy as of Q4 2025, including a 5,000-patient increase from Q3 — early in its adoption curve with the Ocrevus franchise targeting CHF 9 billion. Opdivo Qvantig and Tecentriq Hybreza are similarly early, as is Rybrevant subcutaneous. Each of these drugs, as it ramps through adoption over the next three to five years, will contribute an incremental royalty stream that does not yet appear meaningfully in the 2025 royalty line. And beyond the commercial portfolio, approximately 50 partner drug candidates remain in pre-commercial development — each representing a future royalty stream that has not yet been approved, not yet been commercialized, and not yet contributed a single dollar to the revenue table above.

Halozyme has captured royalty revenue from approximately fifteen commercial products as of early 2026 — against a universe of several hundred approved biologics where subcutaneous conversion could be clinically and commercially beneficial, and against the pipeline of new biologics entering development each year. The 2026 pipeline management is actively building includes fifteen partner programs in clinical development and management's guidance of at least three new licensing agreements to be signed in 2026 — including one to two Hypercon collaborations that represent the first commercial deployment of the new technology platforms. The depth of the pre-commercial pipeline and the scope of new partnerships being signed are the leading indicators for royalty revenue five years from now; the current trajectory is accumulating the building blocks for continued compounding.

At $66.48 per share as of March 22, 2026, Halozyme's market capitalization is $7.85 billion with an enterprise value of $8.28 billion. The trailing P/E on GAAP 2025 earnings is approximately 24 times; the more meaningful forward P/E, based on 2026 non-GAAP EPS guidance of $7.75 to $8.25, is approximately 8.5 times. EV/EBITDA is approximately 10.2 times on 2026 guided EBITDA. For context, royalty-based companies with stable, growing income streams — specialty royalty vehicles, infrastructure royalty trusts — typically trade at 18 to 25 times earnings. Halozyme trades at less than half that range. The discount persists because the stock is classified as a biotechnology company, not a royalty company, and biotech investors applying standard frameworks see patent expiration risk and GAAP earnings distorted by acquisition accounting rather than a royalty machine compounding at 52% annually. The business deserves valuation by the same framework applied to any asset that produces a growing, durable, capital-light income stream.

Computing normalized pre-tax earnings: 2026 guided adjusted EBITDA of $1.165 billion at the midpoint, less approximately $80 million in stock-based compensation (a real cost that should not be excluded) and approximately $50 million in interest expense on acquisition-related debt, yields normalized pre-tax earnings of approximately $1.035 billion, or $8.77 per share on approximately 118 million diluted shares. At $66.48, the stock trades at approximately 7.6 times normalized pre-tax earnings — well below the 15 times threshold at which valuation becomes stretched for a business of this quality. A royalty infrastructure business with a 64.75% EBITDA margin, a 124% return on equity, a 52% royalty growth rate, three delivery technology platforms extending into the 2040s, and a pre-commercial pipeline of approximately 50 partner drugs should not be available at 7.6 times pre-tax earnings. It currently is.

The intelligent bear argues that the patent cliff in 2029 represents a structural risk that the 7.6 times multiple is already correctly discounting. The answer is threefold: the collaboration patents filed with each pharmaceutical partner for each drug extend specific royalty protections beyond the core ENHANZE patent term; the acquisition of Hypercon and Surf Bio technologies creates two additional royalty platforms with IP into the mid-2040s, meaning a new generation of licensing agreements is already being signed on a twenty-year royalty horizon; and the Merck litigation — Halozyme's decision to sue a major pharma company for SC Keytruda infringement rather than walk away — is the clearest available signal of management's confidence in the durability of the patent position. The 2029 risk is real and investors should monitor patent development progress. It is not sufficient to explain an 8.5 times forward earnings multiple for a business growing royalties at 52% annually.

For the thesis to weaken, the royalty compounding would need to decelerate materially — driven by partner drug market share loss, an adverse outcome in the Merck litigation, or commercial failure of the second wave (Ocrevus, Opdivo, Tecentriq). DARZALEX SC holds 97% U.S. market share in the multiple myeloma franchise; VYVGART Hytrulo is expanding into new indications; none of the three established blockbusters show commercial deceleration. No competing subcutaneous delivery technology has achieved a commercial launch. The current period is one of peak established royalty growth coinciding with the early adoption of three new commercial launches — the precise moment when the compounding base expands most rapidly.

A royalty business with a 124% return on equity, growing its income stream at 52% annually, serving the fastest-growing category in pharmaceuticals, with a pipeline of 50 partner drugs waiting to enter commercialization: at 8.5 times forward earnings, the market is effectively valuing the existing royalties and discounting the pipeline entirely. The pipeline is not free — it was built over fifteen years — but at the current price, it is being given away.